Ramos Alexander D, Magge Rajiv S, Ramakrishna Rohan
Department of Neurological Surgery, Weill Cornell Medical College, New York, New York, USA.
Department of Neurology, Weill Cornell Medical College, New York, New York, USA.
World Neurosurg. 2018 Aug;116:495-504. doi: 10.1016/j.wneu.2018.04.021.
Glioblastoma is the most common primary malignant brain tumor, with more than10,000 new cases each year in the United States. Significant basic science and clinical research has been devoted to understanding this disease, yet median survival with standard of care treatment remains approximately 15 months. Over the past decade, advances in genomic sequencing technology, biostatistics, and computing have allowed for an unprecedented ability to profile the gene expression patterns and mutations driving the formation of tumors. These advances have generated both prognostic information as well as a multitude of treatment targets that are just now coming into clinical practice. This article aims to provide a comprehensive update on the recent use of genetic profiling to identify the molecular pathways altered in glioblastoma and to describe ongoing clinical trials to exploit these pathways for treatment.
胶质母细胞瘤是最常见的原发性恶性脑肿瘤，在美国每年有超过10000例新发病例。大量基础科学和临床研究致力于了解这种疾病，但采用标准治疗方案时的中位生存期仍约为15个月。在过去十年中，基因组测序技术、生物统计学和计算领域的进展使人们以前所未有的能力描绘驱动肿瘤形成的基因表达模式和突变情况。这些进展既产生了预后信息，也带来了众多刚刚进入临床实践的治疗靶点。本文旨在全面更新近期利用基因谱分析来识别胶质母细胞瘤中改变的分子途径，并描述利用这些途径进行治疗的正在进行的临床试验。
